#United States #San Diego #Class Action #Berger Montague #Skye Bioscience

Lawsuit Overview: Skye Bioscience, Inc. Under Fire

On December 18, 2025, Berger Montague, a prominent national plaintiffs' law firm, announced the filing of a class action lawsuit against Skye Bioscience, Inc., a biotechnology firm publicly traded on NASDAQ under the ticker SKYE. This lawsuit targets investors who purchased Skye's securities between November 4, 2024, and October 3, 2025, a time frame designated as the "Class Period".

Allegations Against Skye Bioscience

The core of the lawsuit centers on allegations that Skye Bioscience misled investors regarding the effectiveness of their primary product candidate, nimacimab. The complaint claims that Skye failed to disclose critical information that the efficacy of nimacimab was significantly less than what was presented to stakeholders. As a consequence, it is believed that the clinical and commercial potential of this drug was exaggerated, leading to misleading expectations and financial losses for those who invested during this period.

Financial Impact of the Allegations

On October 6, 2025, after Skye disclosed disappointing results from their 26-week Phase 2a CBeyond proof-of-concept study of nimacimab, there was a dramatic collapse in its stock value. The company announced that it did not meet the primary endpoint of achieving an 8% difference in weight loss compared to a placebo, which led to a staggering drop in share price of $2.85, or a 60% decline, bringing the price down to $1.90 at the close of the trading day.

Class Action Participation

Investors who acquired Skye’s securities during the designated Class Period have until January 16, 2026, to apply for appointment as lead plaintiff representatives in the class action. This is a crucial timeline for those looking to protect their financial interests and seek restitution for their losses.

For more information on how to participate or to learn their rights, affected investors are prompted to reach out to the contact persons at Berger Montague.

About Skye Bioscience

Headquartered in San Diego, Skye Bioscience is a clinical-stage biotechnology entity specializing in the development of treatments for obesity and metabolic-related diseases. With nimacimab positioned as its lead candidate, the failure of this product to meet efficacy expectations poses significant questions regarding the company's future initiatives and trustworthiness among investors.

Contact Information

For further clarification or to express interest in participating in the class action suit, investors can get in touch with Andrew Abramowitz, Senior Counsel at Berger Montague, via phone at (215) 875-3015 or email at andrew@[email protected]. Additionally, Caitlin Adorni, Director of Portfolio & Institutional Client Monitoring Services, can be contacted at (267) 764-4865 or [email protected]

About Berger Montague

Berger Montague is a highly regarded law firm that concentrates on complex civil cases, particularly class actions and mass torts across federal and state courts in the U.S. Over the past five decades, the firm has successfully secured over $50 billion in recoveries for clients and focuses on areas such as antitrust, consumer protection, and securities fraud cases. With operations extending to multiple cities including Philadelphia, Chicago, and San Francisco, Berger Montague is well-positioned to advocate for investors affected by Skye's actions.

This lawsuit not only marks a significant moment for Skye Bioscience but also spotlights the enduring importance of transparency and accountability in the biotechnology sector, particularly regarding clinical data reporting and investor relations.

As this case unfolds, many will be watching closely to see how the legal proceedings will influence both the defendants and the broader market surrounding biopharmaceutical investments.